No images? Click here Friday, 22 October 2021 Please find below a comprehensive resource of WHO’s most recent COVID-19 digital content. Much of the content is available in open art files and in more than ten languages. We invite journalists and media outlets to use these assets to help inform your stories and on your social media platforms. Digital content like this is regularly featured in WHO newsletters - you can sign up for those here and in our digital asset management library: COVID-19 / COVID-19 vaccines / ACT Accelerator and COVAX
Vaccine equity animationsCOVID-19 stories![]() "Send 5 Billion Masks, Please" - Interview with WHO Logistics Lead (podcast) EN Uruguay is steadily immunizing itself against COVID-19 (photo essay) EN ES Moldovan pharmacies contribute to pandemic response as a reliable source of information on COVID-19 vaccination DE EN FR RU COVID-19 vaccination in Mauritania EN India: COVID-19 and mental health: Laxmi's story (video) EN HI Somalia pioneers implementation of an integrated disease surveillance and response strategy in a fragile setting EN Vaccination campaign boosts coverage in Samoa EN Vaccines explained1. How do vaccines work?
2. How are vaccines developed?
3. Manufacturing, safety and quality control of vaccines
4. The different types of COVID-19 vaccines 5. How will there be equitable allocation of limited supplies? 6. Country readiness for COVID-19 vaccines 7. The effects of virus variants on COVID-19 vaccines
8. Safety of COVID-19 vaccines 9. Getting the COVID-19 vaccine 10. Side effects of COVID-19 vaccines
11. How to talk about vaccines 12. Vaccine efficacy, effectiveness and protection All Vaccines Explained content AR EN ES FR PT RU ZH Content in this series is available for you to adapt and use. All scripts and art files in Arabic, Chinese, English, French, Hindi, German, Italian, Portuguese and Spanish are available here. If you need help or have questions contact Diane Abad-Vergara. More COVID-19 vaccine resources
COVID-19 course updatesWHO’s online learning platform OpenWHO.org hosts 5.8 million enrolments across courses in 57 languages. All courses are available for free, including 39 courses for COVID-19. NEW COURSES:
NEW FEATURES:
OpenWHO continues to add resources in national and local languages, most recently launching courses in Azerbaijani, Esperanto, Maithili, Nepali and Telugu. The platform also hosts 77 courses on other topics for health emergencies and WHO areas of expertise. Social media tools and digital collaborations![]() Go ViralGO VIRAL! helps protect you against COVID-19 misinformation. You’ll learn about some of the most common ways false and misleading information about the virus are spread. Understanding these tricks allows you to resist them the next time you come across them online. A social media toolkit for healthcare practitionersTo empower doctors and nurses – some of the most effective and trusted messengers of public health information – to actively address COVID-19 misinformation and build vaccine confidence globally, the WHO welcomes this social media toolkit for healthcare practitioners, developed by the Government of the United Kingdom. Leveraging data insights to keep communities informedWHO works with several technology partners to obtain industry-leading insights that help us identify burgeoning misinformation online. These insights allow WHO to target science-based health information where it’s needed most and in languages and formats audiences prefer to engage with. The science of COVID-19WHO experts explain the science related to COVID-19. This video and audio series is available weekly on WHO's social media channels and on Spotify, Apple Podcasts and other major podcasts platforms. Episode transcripts are available for download: AR EN ES FR PT RU ZH NEW: Episode #53 - COVID-19 Booster Shots: What does evidence say so far about safety and effectiveness of booster shots? Are there groups who may need them? Should the world be considering booster shots at this stage of the pandemic? WHO's Dr Katherine O’Brien explains. New or updated Q&As, initiatives and technical guidanceHypertension and COVID-19: scientific brief NEW: AR EN FR Preventing and mitigating COVID-19 at work: Policy brief AR EN ES RU ZH NEW: FR Holding gatherings during the COVID-19 pandemic: WHO policy brief NEW: EN ES FR RU ZH Small public gatherings UPDATED: AR EN ES FR RU ZH Travel advice for the general public NEW: AR EN ES FR RU ZH Technical considerations for implementing a risk-based approach to international travel in the context of COVID-19 NEW: AR EN ES FR RU ZH Policy considerations for implementing a risk-based approach to international travel in the context of COVID-19 NEW: AR EN ES FR RU ZH Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities NEW: AR EN ES FR RU ZH Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health EN NEW: AR Tracking SARS-CoV-2 variants page with new VOI NEW: AR EN ES FR RU ZH Guidance for surveillance of SARS-CoV-2 variants NEW: AR EN ES FR RU ZH Considerations for quarantine of contacts of COVID-19 cases EN NEW: AR ES FR RU ZH Contact tracing for responders EN NEW: AR ES FR RU ZH Operational guide for engaging communities in contact tracing EN NEW: AR ES FR RU ZH Therapeutics and COVID-19 NEW: AR EN ES FR RU ZH WHO COVID-19 Solidarity Therapeutics Trial NEW: AR EN RU ZH COVID-19 case management capacities: diagnostics, therapeutics, vaccine readiness, and other health products - facility assessment tool NEW: AR EN ES FR RU Continuity of essential health services: facility assessment tool: a module from the suite of health service capacity assessments in the context of the COVID-19 pandemic EN NEW: AR ES FR RU Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers EN NEW: ES FR Critical preparedness, readiness and response actions for COVID-19 EN NEW: AR ES FR RU ZH Considerations for implementing and adjusting public health and social measures in the context of COVID-19 NEW: AR EN ES FR RU ZH Community needs, perceptions and demand: community assessment tool AR EN ES ZH NEW: RU Aide memoire: use of medical and non-medical/fabric masks for community outreach activities during the COVID-19 pandemic EN NEW: ES FR COVID-19 vaccines and people living with HIV EN NEW: AR ES FR RU ZH Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm AR EN FR RU NEW: ES ZH Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac EN NEW: AR ES FR RU ZH Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine EN NEW: AR ES FR RU ZH Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 EN NEW: AR ES FR RU ZH Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing EN NEW: AR ES FR RU ZH Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) NEW: AR EN ES FR RU ZH Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19) NEW: AR EN ES FR RU Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2: an evaluation using the test-negative design: guidance document EN NEW: ES FR RU Guidance on conducting vaccine effectiveness evaluations in the setting of new SARS-CoV-2 variants NEW: AR EN ES FR RU ZH More resourcesAll COVID-19 information AR EN ES FR RU ZH Case numbers and vaccination data dashboard and map You are receiving this email because you subscribed. |